275 Grove St., Suite 101C, Newton, MA 02466
+1 617 454 9300
2520 Meridian Parkway, Research Triangle Park, Suite 200, Durham, NC 27713
+1 919 544 3170
© 2000-2022. Parexel International Corporation.
275 Grove St., Suite 101C, Newton, MA 02466
+1 617 454 9300
2520 Meridian Parkway, Research Triangle Park, Suite 200, Durham, NC 27713
+1 919 544 3170
© 2000-2022. Parexel International Corporation.
BY Yuexia Li and Robert Iser - 7.31.19 -
The pharmaceutical facility current Good Manufacturing Practice (cGMP) inspections are the key to ensure the quality of drugs/medicines for the patients around of the world. While it is critical for ensuring the drug product quality, it is also time consuming, and affected by many factors including regional regulations and cultural differences. In today’s global environment, harmonizing the quality standards for manufacturing facility inspections plays an important role in securing the drug supply for patients around the world. The Mutual Recognition Agreement (MRA) between the US FDA and European Union (EU) countries was created to meet such a role.
The Food and Drug Administration Safety and Innovation Act (FDASIA) enacted in 2012 paved the road for the MRA to become legally possible in the US. Under FDASIA, the FDA has the authority to enter into agreements to recognize drug inspections conducted by foreign regulatory authorities, if the FDA determined those authorities can conduct inspections that meet U.S. requirements.
In May 2014, FDA and EU started collaboration to evaluate the way they could each inspect drug manufacturers and assess the risks and benefits of mutual recognition of drug inspections. The MRA took effect on November 1, 2017 with 9 countries as initial participants (USA and 8 EU countries). Since then, a total of 28 EU countries and USA have joined the MRA with the last one, Slovakia joining on July 11, 2019. A time table of when countries joined is as follow:
Country |
Name of the regulatory authority for medicinal products for human use |
Date Under MRA |
Slovakia 2 |
State Institute for Drug Control / Štátny ústav pre kontrolu liečiv (ŠÚKL) |
July 11, 2019 |
Germany 1 |
Zentralstelle der Länder für Gesundheitsschutz bei Arzneimitteln und Medizinprodukten (ZLG) |
June 26, 2019 |
Luxembourg 1 |
Minìstere de la Santé, Division de la Pharmacie et des Médicaments |
June 10, 2019 |
Netherlands 1 |
Healthcare Inspectorate / Inspectie voor de Gezondheidszorg (IGZ) |
June 10, 2019 |
Bulgaria 1 |
Bulgarian Drug Agency ИЗПЪЛНИТЕЛНА АГЕНЦИЯ ПО ЛЕКАРСТВАТА |
April 29, 2019 |
Cyprus 1 |
Minnistry of Health – Pharmaceutical Services Φαρμακευτικές Υπηρεσίες, Υπουργείο Υγείας |
April 29, 2019 |
Poland 1 |
The Main Pharmaceutical Inspectorate/ Główny Inspektorat Farmaceutyczny (GIF) |
February 7, 2019 |
Slovenia 1 |
Agency for Medicinal Products and Medical Devices of the Republic of Slovenia Javna agencija Republike Slovenije za zdravila in medicinske pripomočke (JAZMP) |
February 7, 2019 |
Estonia 1 |
State Agency of Medicines / Ravimiamet |
November 28, 2018 |
Belgium 1 |
Federal agency for medical and health products / Fedraal Agentschap voor geneesmiddelen en gezondheidsproducten/ Agence fédérale des médicaments et produits de santé |
November 16, 2018 |
Denmark 1 |
Danish Medicines Agency / Laegemiddelstyrelsen |
November 16, 2018 |
Finland 1 |
Finnish Medicines Agency / Lääkealan turvallisuus- ja kehittämiskeskus (FIMEA) |
November 16, 2018 |
Latvia 1 |
State Agency of Medicines / Zāļu valsts aģentūra |
November 16, 2018 |
Portugal 1 |
National Authority of Medicines and Health Products / INFARMED, I.P / Autoridade Nacional do Medicamento e Produtos de Saúde, I.P |
September 14, 2018 |
Ireland 1 |
Health Products Regulatory Authority (HPRA) |
June 1, 2018 |
Lithuania 1 |
State Medicines Control Agency / Valstybinė vaistų kontrolės tarnyba |
June 1, 2018 |
Greece 1 |
National Organisation for Medicines |
March 1, 2018 |
Hungary 1 |
National Institute of Pharmacy and Nutrition |
March 1, 2018 |
Czech Republic 1 |
State Institute for Drug Control |
March 1, 2018 |
Romania 1 |
National Agency for Medicines and Medical Devices |
March 1, 2018 |
United States 1 |
Food and Drug Administration |
November 1, 2017 |
Austria 1 |
Austrian Agency for Health and Food Safety / Österreichische Agentur für Gesundheit und Ernährungssicherheit (GmbH) |
November 1, 2017 |
Croatia 1 |
Agency for Medicinal Products and Medical Devices / Agencija za lijekove i medicinske proizvode (HALMED) |
November 1, 2017 |
France 1 |
French National Agency for Medicines and Health Products Safety / Agence nationale de sécurité du medicament et des produits de santé |
November 1, 2017 |
Italy 1 |
Italian Medicines Agency / Agenzia Italiana del Farmaco |
November 1, 2017 |
Malta 3 |
Medicines Regulatory Authority |
November 1, 2017 |
Spain 1 |
Spanish Agency of Medicines and Medical Devices/ Agencia Española de Medicamentos y Productos Sanitarios |
November 1, 2017 |
Sweden 1 |
Medical Products Agency / Läkemedelsverket |
November 1, 2017 |
United Kingdom 1 |
Medicines and Healthcare products Regulatory Agency |
November 1, 2017 |
Information cited in this article is from:
1. The capability determinations apply to routine surveillance inspections. In the future the following product and inspection types may be included in the coverage of the agreement, and this is pending further consideration:
· Vaccines for human use
· Plasma derived pharmaceuticals
· Investigational products (clinical trial material)
· Veterinary products
2. Slovakia – only for inspections of chemically synthesized active pharmaceutical ingredients intended for use in drug products for human oral administration and manufactured in a dedicated, single product facility.
3. Malta - capability excludes sterile or aseptically processed drugs and biological products; and non-sterile, highly potent drug products.
It should be noted that the following are excluded from the scope of MRA:
· human blood
· human plasma
· human tissues
· human organs
· veterinary immunologicals
Now with the MRA in-place, FDA is collaborating with the MRA participants and is reviewing their recent inspection reports and related information in determining each manufacturer’s suitability for the U.S. market in lieu of an FDA site inspection.
The benefits of MRA is apparent and plays key role in the global harmonization and standardization of the quality of manufacturing facility for producing human drugs. Specifically:
· The MRA provides greater efficiencies for US and EU regulatory systems by avoiding a duplication of inspections, and
· The MRA enables reallocation of resources towards inspection of drug manufacturing facilities with potentially higher public health risks across the globe, as such, preventing low quality or even dangerous medicinal products entering into the market places.
FDA will continue to perform some inspections in EU countries with capable inspectorates, such as product specific, pre-approval inspections that support marketing approval decisions. However, FDA expects to perform fewer routine surveillance inspections in EU countries with a capable inspectorate.
The implementation of US-EU MRA is yet another great example of collaboration that creates a win-win situation for regulatory authorities globally.
The MRA took effect on November 1, 2017 with 9 countries as initial participants (USA and 8 EU countries). Since then, a total of 28 EU countries and USA have joined the MRA with the last one, Slovakia joining on July 11, 2019.
Maintaining Data Integrity for Quality and Compliance – Essential Despite Pandemic Disruptions
Read article
New FDA Guidance Addresses the Need for Data-Generation Strategies Across the Drug Development Lifecycle
Read article
RBQM Podcast Series | Episode 2: Cultivating Risk-based Behaviors
Listen now
We are always available for a conversation.